Anygen Co., Ltd. (KOSDAQ: 196300)

South Korea flag South Korea · Delayed Price · Currency is KRW
12,800
-650 (-4.83%)
Dec 20, 2024, 9:00 AM KST
-12.03%
Market Cap 76.84B
Revenue (ttm) 6.12B
Net Income (ttm) -8.67B
Shares Out 6.00M
EPS (ttm) -1,452.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 237,214
Open 13,450
Previous Close 13,450
Day's Range 12,570 - 14,500
52-Week Range 9,000 - 19,000
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About Anygen

Anygen Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It develops GMP, generic, custom, and catalog peptides, as well as offers other services. The company is also developing AGM-331 targeted for anti-cancer therapy, currently under pre-clinical development phase; AGM-130 indicated for the treatment of triple negative breast cancer, currently under Phase I development phase; AGM-380 indicated for the treatment of viral infection, currently ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 196300
Full Company Profile

Financial Performance

In 2023, Anygen's revenue was 5.61 billion, a decrease of -35.23% compared to the previous year's 8.66 billion. Losses were -9.08 billion, 46.3% more than in 2022.

Financial Statements

News

There is no news available yet.